Treatment of patients having c-met exon 14 skipping mutations

A method of treating a subject having a cancer that is positive for a c-Met exon 14 skipping mutation, the method comprising administering to the subject a combination therapy comprising:

• a therapeutically effective amount of an isolated bispecific anti-epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody;
• and
• a therapeutically effective amount of a compound of formula (I)
• or a pharmaceutically acceptable solvate, hydrate, tautomer, or salt thereof, wherein the bispecific anti-EGFR/c-Met antibody comprises:
• a first domain that binds EGFR, the first domain comprising a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence of SEQ ID NO:
• 1, a HCDR2 comprising the amino acid sequence of SEQ ID NO:
• 2, a HCDR3 comprising the amino acid sequence of SEQ ID NO:
• 3, a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence of SEQ ID NO:
• 4, a LCDR2 comprising the amino acid sequence of SEQ ID NO:
• 5, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:
• 6;
• and
• a second domain that binds c-Met, the second domain comprising a HCDR1 comprising the amino acid sequence of SEQ ID NO:
• 7, a HCDR2 comprising the amino acid sequence of SEQ ID NO:
• 8, a HCDR3 comprising the amino acid sequence of SEQ ID NO:
• 9, a LCDR1 comprising the amino acid sequence of SEQ ID NO:
• 10, a LCDR2 comprising the amino acid sequence of SEQ ID NO:
• 11, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:
• 12.